A citation-based method for searching scientific literature

Satish K Garg. Diabetes Technol Ther 2017
Times Cited: 5







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Satish K Garg, Stuart A Weinzimer, William V Tamborlane, Bruce A Buckingham, Bruce W Bode, Timothy S Bailey, Ronald L Brazg, Jacob Ilany, Robert H Slover, Stacey M Anderson,[...]. Diabetes Technol Ther 2017
221
40

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
689
40

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.
Grazia Aleppo, Katrina J Ruedy, Tonya D Riddlesworth, Davida F Kruger, Anne L Peters, Irl Hirsch, Richard M Bergenstal, Elena Toschi, Andrew J Ahmann, Viral N Shah,[...]. Diabetes Care 2017
100
40

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
172
40



Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies.
Janet B McGill, Andrew Ahmann. Diabetes Technol Ther 2017
15
20

Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team.
J A Tamada, S Garg, L Jovanovic, K R Pitzer, S Fermi, R O Potts. JAMA 1999
128
20



CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.
Vivian A Fonseca, George Grunberger, Henry Anhalt, Timothy S Bailey, Thomas Blevins, Satish K Garg, Yehuda Handelsman, Irl B Hirsch, Eric A Orzeck, Victor Lawrence Roberts,[...]. Endocr Pract 2016
92
20

Use of continuous glucose monitoring to improve diabetes mellitus management.
Samuel L Ellis, Tevin Bookout, Satish K Garg, Kenneth E Izuora. Endocrinol Metab Clin North Am 2007
12
20

Managing diabetes in the digital age.
Viral N Shah, Satish K Garg. Clin Diabetes Endocrinol 2015
27
20


Closed-loop system in the management of diabetes: past, present, and future.
Viral N Shah, Aaron Shoskes, Beshoy Tawfik, Satish K Garg. Diabetes Technol Ther 2014
29
20

Future of Automated Insulin Delivery Systems.
Jessica R Castle, J Hans DeVries, Boris Kovatchev. Diabetes Technol Ther 2017
14
20

Stability, Accuracy, and Risk Assessment of a Novel Subcutaneous Glucose Sensor.
Jonathan Hughes, John B Welsh, Naresh C Bhavaraju, Stephen J Vanslyke, Andrew K Balo. Diabetes Technol Ther 2017
4
25

A Simple Composite Metric for the Assessment of Glycemic Status from Continuous Glucose Monitoring Data: Implications for Clinical Practice and the Artificial Pancreas.
Irl B Hirsch, Andrew K Balo, Kevin Sayer, Arturo Garcia, Bruce A Buckingham, Thomas A Peyser. Diabetes Technol Ther 2017
20
20


CGM, Pregnancy, and Remote Monitoring.
Sarit Polsky, Rachel Garcetti. Diabetes Technol Ther 2017
17
20

Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use.
Gregory P Forlenza, Nicholas B Argento, Lori M Laffel. Diabetes Technol Ther 2017
22
20

Flash Glucose Monitoring: The Future Is Here.
Satish K Garg, Halis Kaan Akturk. Diabetes Technol Ther 2017
15
20

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Satish K Garg, Karin Wernicke-Panten, Maria Rojeski, Suzanne Pierre, Yvonne Kirchhein, Krystyna Jedynasty. Diabetes Technol Ther 2017
15
20

Updates on cardiovascular outcome trials in diabetes.
Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello. Cardiovasc Diabetol 2017
32
20

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus.
Ahmet Afşin Oktay, Halis Kaan Akturk, Kerim Esenboğa, Fahad Javed, Nichole M Polin, Eiman Jahangir. Curr Probl Cardiol 2018
5
20

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
Kathrin Herrmann, Steven C Brunell, Yan Li, Ming Zhou, David G Maggs. Adv Ther 2016
10
20

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
116
20

SGLT inhibition and euglycaemic diabetic ketoacidosis.
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones, Roselle Herring. Lancet Diabetes Endocrinol 2015
48
20

Diabetes mellitus and hypertension: a dual threat.
Ahmet Afşin Oktay, Halis Kaan Akturk, Eiman Jahangir. Curr Opin Cardiol 2016
16
20

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Susanne Famulla, Thomas R Pieber, Jens Eilbracht, Dietmar Neubacher, Nima Soleymanlou, Hans J Woerle, Uli C Broedl, Stefan Kaspers. Diabetes Technol Ther 2017
29
20


Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
86
20

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
142
20

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Gian Paolo Fadini, Benedetta Maria Bonora, Angelo Avogaro. Diabetologia 2017
85
20

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
23
20

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
152
20


Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
50
20

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
136
20


Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent.
Hillel Sternlicht, George L Bakris. Nat Rev Nephrol 2016
2
50

Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Robert L Dobbins, Frank L Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan M Andrews, Jeffrey A Wald, Ann Walker, Chari D Smith. Am J Physiol Gastrointest Liver Physiol 2015
62
20

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
35
20


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
20


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
20

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
96
20


Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
866
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.